ClinicalTrials.Veeva

Menu

Effect of Perineural Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Ankle Surgery

T

Tampere University Hospital

Status and phase

Completed
Phase 4

Conditions

Postoperative Pain
Nerve Block

Treatments

Drug: Dexamethasone Sodium Phosphate
Drug: Sodium Chloride 9mg/mL
Drug: Ropivacaine Hydrochloride Inj 2 mg/ml

Study type

Interventional

Funder types

Other

Identifiers

NCT03332316
2017-002185-51 (EudraCT Number)
R17104M

Details and patient eligibility

About

Effect of perineural dexamethasone on the duration of popliteal nerve block after ankle/foot surgery

Full description

This study is proposed to explore the effect of perineural dexamethasone on the duration of popliteal nerve block for analgesia after ankle surgery.

After ankle or foot arthrodesis patients need a good analgesia. Nevertheless early mobilisation and discharge are important for the healing process after surgery. Peripheral nerve blocks have provided a safe, effective method to control early postoperative pain when symptoms are most severe. Perineural dexamethasone added to local anesthetic prolongs the duration of analgesia of the perineural nerve block.

The perineural use of dexamethasone is still off-label. There is a ongoing discussion of which has better benefits, intravenous or perineural dexamethasone.

There are multiple research where the intravenous and perineural dexamethasone use has compared, but there is still a limited amount of research of low dose perineural dexamethasone versus intravenous dexamethasone.

In this study investigators compare different doses of perineural dexamethasone added to ropivacaine 2 mg/ml 20ml. After arthrodesis under spinal anaesthesia the patients receive popliteal block ropivacaine 2 mg/ml 20 ml and dexamethasone of different doses. Groups 1 to 4 has dexamethasone doses 0, 2mg, 3mg or 4 mg.

After the popliteal nerve block investigators follow postoperative pain, opiate consumption, mobilisation and long term quality of life.

Investigators goal is to find a dexamethasone dose which is as low as possible but at the same time covers the need for a good pain relief and fast recovery postoperatively.

Enrollment

84 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult people under ankle/foot arthrodesis as a curative therapy of ankle arthrosis or situation after ankle injury or malposition

Exclusion criteria

Age under 18 years Complicated diabetes mellitus Lack of finnish language skill and/or co-operation Chronic pain Steroid medication in regular use

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

84 participants in 4 patient groups, including a placebo group

DEXA0
Placebo Comparator group
Description:
Ropivacaine Hydrochloride Inj 2mg/ml 20 ml and Sodium Chloride 9mg/mL 1 ml perineurally
Treatment:
Drug: Sodium Chloride 9mg/mL
Drug: Ropivacaine Hydrochloride Inj 2 mg/ml
DEXA1
Experimental group
Description:
Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,2 ml and Sodium Chloride 9mg/mL 0,8 ml perineurally
Treatment:
Drug: Sodium Chloride 9mg/mL
Drug: Ropivacaine Hydrochloride Inj 2 mg/ml
Drug: Dexamethasone Sodium Phosphate
DEXA2
Experimental group
Description:
Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,4 ml and Sodium Chloride 9mg/mL 0,6 ml perineurally
Treatment:
Drug: Sodium Chloride 9mg/mL
Drug: Ropivacaine Hydrochloride Inj 2 mg/ml
Drug: Dexamethasone Sodium Phosphate
DEXA4
Experimental group
Description:
Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,8 ml and Sodium Chloride 9mg/mL 0,2 ml perineurally
Treatment:
Drug: Sodium Chloride 9mg/mL
Drug: Ropivacaine Hydrochloride Inj 2 mg/ml
Drug: Dexamethasone Sodium Phosphate

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems